Wednesday, 08 May 2019｜Source：CHINA CHAMBER OF COMMERCEFOR IMPORT&EXPORT OF MEDICINES &HEALTH PRODUCTS｜Author：
In 2018，The export value of FPPs was $4.01 billion, 18.64% year-on-year growth. Regulating market in strong growth, EU, Australia, and the US market ranked among the top 3, with $1.207 billion, $422 million and &387 million respectively. In the past two years, the exports to the EU market have grown rapidly, with an increase of 53.51% in 2017. In 2018, the growth rate reached a new high of 80.30% and the export volume was $1.207 billion
In recent years, the export of FPPs has become one of the important logo of Chinese pharmaceutical companies have gone out. The data shows that in 2018, FPPs exported to developed markets of $2.372 billion, 38.39% year-on-year growth. The growth of the Eu, American and Japanese regulated markets was very significant, with growth rates of 80.30%, 24.62% and 27.49% respectively. The increase in the export volume of FPPs is not a day's work. Thanks to the long-term cultivation of Chinese pharmaceutical companies, Huahai Pharmaceutical, Techdow Pharmaceutical, Hengrui Medicine, Qilu Pharmaceutical, and Puracap pharmaceutical have led the development of pharmaceutical products in developed markets.
The approved number of ANDA can also reflect the efforts of Chinese pharmaceutical companies in the export of FPPs from another angle. In 2018, the number of Chinese companies' ANDA approvals reached new record, got 71 ANDA approvals, 16 of which were provisional approvals. Guangdong Dongyangguang, Huahai Pharmaceutical, and Humanwell group were the most approved, with 12, 11 and 6 respectively What is gratifying is that while the number of Chinese companies has been rising, ANDA's applicants have also ushered in new faces. In 2018, enterprises such as Yiling Pharmaceutical, Shandong New Time Pharmaceutical, Hainan Shuangcheng, Boya Seehot Pharmaceutical, Shanghai Desano, Qilu tianhe pharmaceutical were first got approval by ANDA.
Imports of FPPs account for half of the total
For imports, FPPs remain the main import category. The FPPs imported by China are mainly the patented medicines and originator medicies of multinational pharmaceutical enterprises. For a long period of time, even the patents expired, the price of imported medicines remains high due to the bidding and purchasing policy of one product and two regulations, and domestically produced medicines are difficult to the formation of full competition. With the comprehensive advancement of generic drug quality consistency evaluation and negotiation of medical insurance catalogue price in recent two-year ,“4+7” quantity purchasing, other policies and measures to reduce drug prices, Finally, in 2018 the average import price of FPPs fell sharply, with a year-on-year decline of 25.36%. At the same time, although the goverment have also introduced a series of import incentives to anti-cancer drugs, rare diseases and other clinically needed drugs, they are limited by the registration period of drugs and accelerated in domestic drugs. Under the influence of import substitution and multinational pharmaceutical companies' active adjustment of sales strategies in China, the import scale of FPPs has not increased significantly, increase of 1.75%. year on year Under this effect, the import volume reached $13.03 billion, a decrease of 24.05% year-on-year.